Institució Catalana de Recerca i Estudis Avançats-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2025

  1. A TIM-3–Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia

    Blood, Vol. 145, Núm. 22, pp. 2599-2613

2024

  1. Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 64-92

  2. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

    HemaSphere, Vol. 8, Núm. 2

  3. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

    Haematologica

  2. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)

    Frontiers in Pediatrics, Vol. 11

2022

  1. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

    Molecular Therapy, Vol. 30, Núm. 2, pp. 550-563

  2. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

    Molecular Oncology, Vol. 16, Núm. 16, pp. 2899-2919

  3. Near-haploidy and low-hypodiploidy in b-cell acute lymphoblastic leukemia: When less is too much

    Cancers, Vol. 14, Núm. 1

  4. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Engraftment characterization of risk-stratified AML in NSGS mice

    Blood Advances, Vol. 5, Núm. 23, pp. 4842-4854

2020

  1. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 2

  2. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 2

2019

  1. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis

    Haematologica, Vol. 104, Núm. 2, pp. e54-e58

  2. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

    Blood, Vol. 133, Núm. 21, pp. 2291-2304

  3. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

    Leukemia, Vol. 33, Núm. 7, pp. 1557-1569

2018

  1. A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases

    Kidney International, Vol. 94, Núm. 2, pp. 363-371

  2. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML

    OncoImmunology, Vol. 7, Núm. 9

2017

  1. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

    Stem Cell Reports, Vol. 8, Núm. 6, pp. 1573-1586

2016

  1. Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency

    Stem Cell Reports, Vol. 7, Núm. 4, pp. 602-618